const pptxgen = require('pptxgenjs');

const pptx = new pptxgen();
pptx.layout = 'LAYOUT_WIDE';
pptx.author = 'Orris';
pptx.company = 'Medical Education';
pptx.subject = 'Pharmacology - Diagnostic Agents';
pptx.title = 'Diagnostic Agents for Undergraduate Medical Students';
pptx.lang = 'en-US';
pptx.theme = {
  headFontFace: 'Calibri',
  bodyFontFace: 'Calibri',
  lang: 'en-US'
};

const colors = {
  bgDark: '0F172A',
  bgLight: 'F8FAFC',
  primary: '0EA5E9',
  secondary: '1E293B',
  textDark: '0B1324',
  textLight: 'F8FAFC',
  accent: 'F59E0B',
  muted: '475569'
};

function addTitleBar(slide, title, subtitle='') {
  slide.background = { color: colors.bgLight };
  slide.addShape(pptx.ShapeType.rect, {
    x: 0,
    y: 0,
    w: 13.33,
    h: 0.9,
    fill: { color: colors.secondary },
    line: { color: colors.secondary }
  });
  slide.addText(title, {
    x: 0.5,
    y: 0.2,
    w: 10.8,
    h: 0.4,
    fontSize: 24,
    bold: true,
    color: colors.textLight
  });
  if (subtitle) {
    slide.addText(subtitle, {
      x: 0.5,
      y: 1.0,
      w: 12.3,
      h: 0.35,
      fontSize: 14,
      color: colors.muted,
      italic: true
    });
  }
}

function addFooter(slide, text='UG Medical Pharmacology') {
  slide.addShape(pptx.ShapeType.line, {
    x: 0.5,
    y: 7.1,
    w: 12.3,
    h: 0,
    line: { color: 'CBD5E1', pt: 1 }
  });
  slide.addText(text, {
    x: 0.5,
    y: 7.15,
    w: 6,
    h: 0.2,
    fontSize: 10,
    color: '64748B'
  });
}

// Slide 1: Title
let slide = pptx.addSlide();
slide.background = { color: colors.bgDark };
slide.addText('Diagnostic Agents', {
  x: 0.8, y: 1.6, w: 11.8, h: 1,
  fontSize: 50, bold: true, color: colors.textLight
});
slide.addText('Pharmacology for Undergraduate Medical Students', {
  x: 0.8, y: 2.8, w: 11.8, h: 0.6,
  fontSize: 24, color: 'BAE6FD'
});
slide.addShape(pptx.ShapeType.roundRect, {
  x: 0.8, y: 3.8, w: 5.0, h: 0.6,
  fill: { color: colors.primary }, line: { color: colors.primary, pt: 1 }, radius: 0.08
});
slide.addText('20–30 Slide Detailed Lecture Deck', {
  x: 1.0, y: 3.98, w: 4.7, h: 0.3,
  fontSize: 14, color: 'FFFFFF', bold: true
});
slide.addText('Focus: radiocontrast media, MRI contrast agents, safety, and clinical use', {
  x: 0.8, y: 4.8, w: 12, h: 0.5,
  fontSize: 16, color: 'CBD5E1'
});

// Slide 2: Learning objectives
slide = pptx.addSlide();
addTitleBar(slide, 'Learning Objectives');
slide.addText([
  { text: 'Define diagnostic agents and classify major types used in practice.', options: { bullet: { indent: 18 }, breakLine: true } },
  { text: 'Explain physicochemical properties of contrast media (osmolality, viscosity, ionicity).', options: { bullet: { indent: 18 }, breakLine: true } },
  { text: 'Describe pharmacokinetics and mechanisms of adverse effects, especially CA-AKI.', options: { bullet: { indent: 18 }, breakLine: true } },
  { text: 'Identify patient risk factors and evidence-based prevention protocols.', options: { bullet: { indent: 18 }, breakLine: true } },
  { text: 'Differentiate iodinated contrast from gadolinium-based MRI agents.', options: { bullet: { indent: 18 }, breakLine: true } },
  { text: 'Apply principles in clinical scenarios and prescribing safety.', options: { bullet: { indent: 18 } } }
], {
  x: 0.9, y: 1.6, w: 12, h: 4.8, fontSize: 22, color: colors.textDark, margin: 6
});
addFooter(slide);

// Slide 3: Agenda
slide = pptx.addSlide();
addTitleBar(slide, 'Session Agenda');
const agendaItems = [
  '1. Introduction and classification',
  '2. Iodinated radiocontrast agents',
  '3. Contrast-associated AKI (CA-AKI)',
  '4. Prevention and management',
  '5. Gadolinium agents and NSF',
  '6. Hypersensitivity and other adverse effects',
  '7. Practical prescribing pearls and case discussion'
];
slide.addText(agendaItems.join('\n'), {
  x: 1.0, y: 1.5, w: 11.8, h: 4.8, fontSize: 24, color: colors.secondary,
  breakLine: true, margin: 4
});
addFooter(slide);

// Slide 4: What are diagnostic agents?
slide = pptx.addSlide();
addTitleBar(slide, 'What Are Diagnostic Agents?', 'Pharmacological substances used to improve diagnosis rather than to treat disease directly');
slide.addText('Core concept', { x: 0.8, y: 1.6, w: 3, h: 0.4, fontSize: 20, bold: true, color: colors.primary });
slide.addText('Agents administered to enhance visualization, detect physiological abnormalities, or measure organ function during diagnostic procedures.', {
  x: 0.8, y: 2.1, w: 12.0, h: 1.0, fontSize: 20, color: colors.textDark
});
slide.addShape(pptx.ShapeType.roundRect, {
  x: 0.8, y: 3.4, w: 12.0, h: 2.3,
  fill: { color: 'E2E8F0' }, line: { color: 'CBD5E1', pt: 1 }, radius: 0.08
});
slide.addText([
  { text: 'Examples in medicine:\n', options: { bold: true, color: colors.secondary, breakLine: true } },
  { text: '• Iodinated contrast for CT/angiography\n', options: { breakLine: true } },
  { text: '• Gadolinium agents for MRI\n', options: { breakLine: true } },
  { text: '• Radiotracers in nuclear medicine\n', options: { breakLine: true } },
  { text: '• Functional dyes/tests for organ assessment' }
], { x: 1.1, y: 3.7, w: 11.3, h: 1.8, fontSize: 20, color: colors.textDark });
addFooter(slide);

// Slide 5: Classification
slide = pptx.addSlide();
addTitleBar(slide, 'Classification of Diagnostic Agents');
slide.addShape(pptx.ShapeType.rect, { x: 0.8, y: 1.5, w: 5.9, h: 2.2, fill: { color: 'DBEAFE' }, line: { color: '93C5FD', pt: 1 } });
slide.addText('Radiology contrast agents', { x: 1.1, y: 1.8, w: 5.3, h: 0.4, fontSize: 19, bold: true, color: '1E3A8A' });
slide.addText('Iodinated (CT/angiography),\nGadolinium-based (MRI),\nBarium (GI imaging)', { x: 1.1, y: 2.3, w: 5.4, h: 1.2, fontSize: 16, color: '1E3A8A' });

slide.addShape(pptx.ShapeType.rect, { x: 6.7, y: 1.5, w: 5.9, h: 2.2, fill: { color: 'DCFCE7' }, line: { color: '86EFAC', pt: 1 } });
slide.addText('Nuclear medicine tracers', { x: 7.0, y: 1.8, w: 5.3, h: 0.4, fontSize: 19, bold: true, color: '166534' });
slide.addText('Technetium-labeled compounds,\nPET radiotracers', { x: 7.0, y: 2.3, w: 5.4, h: 1.2, fontSize: 16, color: '166534' });

slide.addShape(pptx.ShapeType.rect, { x: 0.8, y: 4.0, w: 11.8, h: 2.0, fill: { color: 'FEF3C7' }, line: { color: 'FCD34D', pt: 1 } });
slide.addText('This lecture focus: Contrast agents used in radiology (most relevant UG pharmacology topic)', { x: 1.1, y: 4.65, w: 11.2, h: 0.8, fontSize: 19, bold: true, color: '92400E', align: 'center' });
addFooter(slide);

// Slide 6: Iodinated contrast overview
slide = pptx.addSlide();
addTitleBar(slide, 'Iodinated Contrast Media: Overview');
slide.addText([
  { text: 'Primary uses: ', options: { bold: true } },
  { text: 'CT scans, CT angiography, catheter angiography, interventional procedures\n', options: { breakLine: true } },
  { text: 'Excretion: ', options: { bold: true } },
  { text: 'mainly renal (glomerular filtration)\n', options: { breakLine: true } },
  { text: 'Clinical concern: ', options: { bold: true } },
  { text: 'contrast-associated AKI in susceptible patients\n', options: { breakLine: true } },
  { text: 'Other concerns: ', options: { bold: true } },
  { text: 'hypersensitivity reactions, extravasation, thyroid effects' }
], { x: 0.9, y: 1.6, w: 12, h: 3.8, fontSize: 22, color: colors.textDark });
addFooter(slide);

// Slide 7: Osmolality and viscosity
slide = pptx.addSlide();
addTitleBar(slide, 'Physicochemical Properties That Matter');
slide.addShape(pptx.ShapeType.rect, { x: 0.8, y: 1.6, w: 3.9, h: 1.5, fill: { color: 'FEE2E2' }, line: { color: 'FCA5A5', pt: 1 } });
slide.addText('HOCM\n(High-osmolar)', { x: 1.1, y: 1.95, w: 3.3, h: 1.0, fontSize: 17, bold: true, color: '991B1B', align: 'center' });
slide.addShape(pptx.ShapeType.rect, { x: 4.8, y: 1.6, w: 3.9, h: 1.5, fill: { color: 'FEF3C7' }, line: { color: 'FCD34D', pt: 1 } });
slide.addText('LOCM\n(Low-osmolar)', { x: 5.1, y: 1.95, w: 3.3, h: 1.0, fontSize: 17, bold: true, color: '92400E', align: 'center' });
slide.addShape(pptx.ShapeType.rect, { x: 8.8, y: 1.6, w: 3.9, h: 1.5, fill: { color: 'DCFCE7' }, line: { color: '86EFAC', pt: 1 } });
slide.addText('IOCM\n(Iso-osmolar)', { x: 9.1, y: 1.95, w: 3.3, h: 1.0, fontSize: 17, bold: true, color: '166534', align: 'center' });

slide.addText('Key teaching points:\n• CA-AKI risk is higher with HOCM than LOCM.\n• IOCM may reduce risk in some CKD groups, but data are mixed.\n• Viscosity can offset osmolality advantages in real-world outcomes.', {
  x: 0.9, y: 3.5, w: 12, h: 2.6, fontSize: 19, color: colors.textDark
});
addFooter(slide);

// Slide 8: Pathophysiology of CA-AKI
slide = pptx.addSlide();
addTitleBar(slide, 'Pathophysiology of Contrast-Associated AKI (CA-AKI)');
slide.addText('Three major mechanisms', { x: 0.8, y: 1.4, w: 4.5, h: 0.5, fontSize: 22, bold: true, color: colors.primary });
slide.addText('1) Renal vasoconstriction (adenosine, endothelin) → medullary ischemia\n2) Direct tubular toxicity and oxidative stress → apoptosis/necrosis\n3) High viscosity → sluggish microcirculation and hypoxia', {
  x: 0.9, y: 2.0, w: 12, h: 2.2, fontSize: 21, color: colors.textDark
});
slide.addShape(pptx.ShapeType.roundRect, { x: 0.9, y: 4.6, w: 12.0, h: 1.3, fill: { color: 'E0F2FE' }, line: { color: '7DD3FC', pt: 1 }, radius: 0.07 });
slide.addText('Clinical pattern: creatinine rises within 24 h, peaks by day 2–5, often returns toward baseline by day 7–14.', {
  x: 1.2, y: 4.95, w: 11.4, h: 0.7, fontSize: 18, bold: true, color: '075985', align: 'center'
});
addFooter(slide);

// Slide 9: Definition and timeline
slide = pptx.addSlide();
addTitleBar(slide, 'Definition and Typical Timeline of CA-AKI');
slide.addShape(pptx.ShapeType.line, { x: 1.0, y: 3.8, w: 11.3, h: 0, line: { color: colors.secondary, pt: 2 } });
const points = [
  { x: 1.2, day: '0 h', txt: 'Contrast exposure' },
  { x: 3.8, day: '24 h', txt: 'Creatinine begins to rise' },
  { x: 7.0, day: '2–5 days', txt: 'Peak creatinine' },
  { x: 10.3, day: '7–14 days', txt: 'Recovery toward baseline' }
];
points.forEach(p => {
  slide.addShape(pptx.ShapeType.ellipse, { x: p.x, y: 3.62, w: 0.35, h: 0.35, fill: { color: colors.primary }, line: { color: colors.primary, pt: 1 } });
  slide.addText(p.day, { x: p.x - 0.2, y: 4.05, w: 1, h: 0.3, fontSize: 14, bold: true, color: colors.secondary, align: 'center' });
  slide.addText(p.txt, { x: p.x - 0.9, y: 4.35, w: 2.2, h: 0.8, fontSize: 13, color: colors.textDark, align: 'center' });
});
slide.addText('Defined as a rise in serum creatinine within 48–72 hours after contrast exposure, after excluding other causes.', {
  x: 0.9, y: 1.9, w: 12, h: 1.0, fontSize: 21, color: colors.textDark
});
addFooter(slide);

// Slide 10: Risk factors
slide = pptx.addSlide();
addTitleBar(slide, 'Risk Factors for CA-AKI');
slide.addText('Patient-related factors', { x: 0.8, y: 1.5, w: 5.8, h: 0.4, fontSize: 20, bold: true, color: '7C2D12' });
slide.addShape(pptx.ShapeType.rect, { x: 0.8, y: 2.0, w: 5.8, h: 3.8, fill: { color: 'FFEDD5' }, line: { color: 'FDBA74', pt: 1 } });
slide.addText('• CKD (especially stage 4+)\n• Older age\n• Volume depletion\n• Heart failure\n• Diabetic kidney disease\n• Hypertension/hypotension\n• Anemia', {
  x: 1.1, y: 2.3, w: 5.2, h: 3.0, fontSize: 18, color: '7C2D12'
});

slide.addText('Procedure-related factors', { x: 6.8, y: 1.5, w: 5.8, h: 0.4, fontSize: 20, bold: true, color: '1E3A8A' });
slide.addShape(pptx.ShapeType.rect, { x: 6.8, y: 2.0, w: 5.8, h: 3.8, fill: { color: 'DBEAFE' }, line: { color: '93C5FD', pt: 1 } });
slide.addText('• High contrast volume\n• Intra-arterial route\n• Coronary angiography\n• Emergent procedures\n• Concurrent nephrotoxins', {
  x: 7.1, y: 2.3, w: 5.2, h: 3.0, fontSize: 18, color: '1E3A8A'
});
addFooter(slide);

// Slide 11: Route and dose relationship
slide = pptx.addSlide();
addTitleBar(slide, 'Dose and Route: Impact on Risk');
slide.addText('Higher dose = higher risk. Use the smallest volume needed for diagnosis.', {
  x: 0.9, y: 1.5, w: 12, h: 0.6, fontSize: 22, bold: true, color: colors.secondary
});
slide.addText('Suggested practical upper limits from nephrology literature:\n• Serum creatinine 1.5–3.4 mg/dL: keep contrast ≤150 mL\n• Serum creatinine >3.4 mg/dL: consider ≤100 mL when feasible', {
  x: 1.0, y: 2.4, w: 12, h: 2.0, fontSize: 19, color: colors.textDark
});
slide.addShape(pptx.ShapeType.roundRect, { x: 1.0, y: 4.8, w: 11.6, h: 1.2, fill: { color: 'DCFCE7' }, line: { color: '86EFAC', pt: 1 }, radius: 0.07 });
slide.addText('Intra-arterial > Intravenous risk. Coronary angiography often carries the highest CA-AKI burden.', {
  x: 1.3, y: 5.1, w: 11.1, h: 0.6, fontSize: 18, bold: true, color: '166534', align: 'center'
});
addFooter(slide);

// Slide 12: Prevention protocol
slide = pptx.addSlide();
addTitleBar(slide, 'Evidence-Based Prevention of CA-AKI');
slide.addText('Most important intervention: isotonic IV fluid before and after contrast exposure.', {
  x: 0.9, y: 1.5, w: 12, h: 0.7, fontSize: 22, bold: true, color: colors.primary
});
slide.addText('Recommended protocol elements:\n• Assess baseline renal function (eGFR, creatinine)\n• Use LOCM/IOCM and lowest possible dose\n• Hydrate with isotonic saline peri-procedure\n• Hold/avoid avoidable nephrotoxic drugs\n• Recheck renal function in high-risk patients', {
  x: 1.0, y: 2.4, w: 12, h: 3.2, fontSize: 19, color: colors.textDark
});
addFooter(slide);

// Slide 13: What not to do
slide = pptx.addSlide();
addTitleBar(slide, 'Interventions With Limited/No Proven Benefit');
slide.addShape(pptx.ShapeType.rect, { x: 0.8, y: 1.8, w: 12.0, h: 3.8, fill: { color: 'FEE2E2' }, line: { color: 'FCA5A5', pt: 1 } });
slide.addText('N-acetylcysteine (NAC): large trials did not show prevention benefit.\nSodium bicarbonate vs saline: no clear superiority in major RCT data.\nRoutine post-contrast dialysis solely to prevent CA-AKI: generally not recommended.', {
  x: 1.1, y: 2.3, w: 11.5, h: 2.6, fontSize: 20, color: '991B1B'
});
slide.addText('Take-home: prioritize volume optimization and risk stratification.', {
  x: 0.9, y: 6.1, w: 12, h: 0.5, fontSize: 19, bold: true, color: colors.secondary, align: 'center'
});
addFooter(slide);

// Slide 14: Gadolinium overview
slide = pptx.addSlide();
addTitleBar(slide, 'Gadolinium-Based Contrast Agents (GBCAs)');
slide.addText('Used in MRI to improve tissue characterization and lesion detection.', { x: 0.9, y: 1.6, w: 12, h: 0.6, fontSize: 21, color: colors.textDark });
slide.addShape(pptx.ShapeType.rect, { x: 0.9, y: 2.4, w: 5.7, h: 3.3, fill: { color: 'E0F2FE' }, line: { color: '7DD3FC', pt: 1 } });
slide.addText('Advantages', { x: 1.2, y: 2.7, w: 5.1, h: 0.4, fontSize: 19, bold: true, color: '075985' });
slide.addText('• Excellent soft-tissue contrast\n• Lower AKI risk at standard doses\n• Valuable in neuro, MSK, oncologic imaging', { x: 1.2, y: 3.2, w: 5.1, h: 2.0, fontSize: 16, color: '075985' });
slide.addShape(pptx.ShapeType.rect, { x: 6.7, y: 2.4, w: 6.0, h: 3.3, fill: { color: 'FEF3C7' }, line: { color: 'FCD34D', pt: 1 } });
slide.addText('Precautions', { x: 7.0, y: 2.7, w: 5.4, h: 0.4, fontSize: 19, bold: true, color: '92400E' });
slide.addText('• Severe CKD: risk of nephrogenic systemic fibrosis (NSF)\n• Prefer safer agents and minimum effective dose\n• Follow current radiology/nephrology protocol', { x: 7.0, y: 3.2, w: 5.4, h: 2.0, fontSize: 16, color: '92400E' });
addFooter(slide);

// Slide 15: Iodinated vs gadolinium
slide = pptx.addSlide();
addTitleBar(slide, 'Iodinated Contrast vs Gadolinium: Quick Comparison');
slide.addText('Feature', { x: 0.9, y: 1.5, w: 2.5, h: 0.4, fontSize: 16, bold: true, color: colors.secondary });
slide.addText('Iodinated', { x: 4.0, y: 1.5, w: 3.8, h: 0.4, fontSize: 16, bold: true, color: colors.secondary });
slide.addText('Gadolinium', { x: 8.2, y: 1.5, w: 3.8, h: 0.4, fontSize: 16, bold: true, color: colors.secondary });

const rows = [
  ['Modality', 'CT/angiography', 'MRI'],
  ['Main elimination', 'Renal', 'Renal'],
  ['Major renal concern', 'CA-AKI', 'NSF (severe CKD)'],
  ['Allergy profile', 'Immediate/delayed reactions', 'Less common but possible'],
  ['Risk reduction', 'Hydration + dose minimization', 'Patient selection + dose minimization']
];
let y = 2.0;
rows.forEach((r, i) => {
  const fill = i % 2 === 0 ? 'F1F5F9' : 'E2E8F0';
  slide.addShape(pptx.ShapeType.rect, { x: 0.9, y, w: 11.8, h: 0.75, fill: { color: fill }, line: { color: 'CBD5E1', pt: 1 } });
  slide.addText(r[0], { x: 1.1, y: y + 0.18, w: 2.5, h: 0.35, fontSize: 14, color: colors.textDark, bold: true });
  slide.addText(r[1], { x: 4.0, y: y + 0.18, w: 3.8, h: 0.35, fontSize: 14, color: colors.textDark });
  slide.addText(r[2], { x: 8.2, y: y + 0.18, w: 3.8, h: 0.35, fontSize: 14, color: colors.textDark });
  y += 0.78;
});
addFooter(slide);

// Slide 16: Hypersensitivity
slide = pptx.addSlide();
addTitleBar(slide, 'Hypersensitivity to Contrast Media');
slide.addText('Clinical spectrum', { x: 0.8, y: 1.5, w: 3.0, h: 0.4, fontSize: 20, bold: true, color: colors.primary });
slide.addText('Mild: nausea, urticaria, pruritus\nModerate: bronchospasm, facial edema, persistent vomiting\nSevere: hypotension, laryngeal edema, anaphylaxis', {
  x: 0.9, y: 2.1, w: 12, h: 2.0, fontSize: 20, color: colors.textDark
});
slide.addShape(pptx.ShapeType.roundRect, { x: 0.9, y: 4.5, w: 12.0, h: 1.4, fill: { color: 'FEE2E2' }, line: { color: 'FCA5A5', pt: 1 }, radius: 0.08 });
slide.addText('Always ensure emergency preparedness during contrast administration: airway support, epinephrine access, monitoring.', {
  x: 1.2, y: 4.9, w: 11.4, h: 0.7, fontSize: 18, bold: true, color: '991B1B', align: 'center'
});
addFooter(slide);

// Slide 17: Special populations
slide = pptx.addSlide();
addTitleBar(slide, 'Special Populations and Practical Considerations');
slide.addText('CKD patients', { x: 0.9, y: 1.6, w: 3.5, h: 0.4, fontSize: 18, bold: true, color: '1E3A8A' });
slide.addText('Use strict risk stratification, hydration, and dose minimization.', { x: 0.9, y: 2.0, w: 12, h: 0.5, fontSize: 17, color: colors.textDark });
slide.addText('Diabetes/heart failure', { x: 0.9, y: 2.8, w: 4.0, h: 0.4, fontSize: 18, bold: true, color: '1E3A8A' });
slide.addText('Optimize volume status and review concomitant nephrotoxic medications.', { x: 0.9, y: 3.2, w: 12, h: 0.5, fontSize: 17, color: colors.textDark });
slide.addText('Emergency procedures', { x: 0.9, y: 4.0, w: 4.0, h: 0.4, fontSize: 18, bold: true, color: '1E3A8A' });
slide.addText('Risk rises because prophylaxis may be limited; reassess after stabilization.', { x: 0.9, y: 4.4, w: 12, h: 0.5, fontSize: 17, color: colors.textDark });
slide.addText('Outpatient CT with eGFR >30 mL/min/1.73 m²', { x: 0.9, y: 5.2, w: 6.5, h: 0.4, fontSize: 18, bold: true, color: '166534' });
slide.addText('Generally lower CA-AKI risk in non-emergent settings.', { x: 0.9, y: 5.6, w: 12, h: 0.5, fontSize: 17, color: colors.textDark });
addFooter(slide);

// Slide 18: Prescribing checklist
slide = pptx.addSlide();
addTitleBar(slide, 'Contrast Prescribing Checklist (For Interns and Students)');
const checklist = [
  '1. Why is contrast needed for this study?',
  '2. What is baseline renal function (eGFR/creatinine)?',
  '3. Is the patient volume depleted?',
  '4. Any history of prior contrast reaction?',
  '5. Can contrast volume be reduced?',
  '6. Is prophylactic isotonic hydration arranged?',
  '7. Are avoidable nephrotoxins held?',
  '8. Is post-procedure monitoring planned?'
];
slide.addText(checklist.join('\n'), { x: 1.0, y: 1.7, w: 11.8, h: 4.7, fontSize: 21, color: colors.textDark });
addFooter(slide);

// Slide 19: Clinical case 1
slide = pptx.addSlide();
addTitleBar(slide, 'Case Discussion 1');
slide.addShape(pptx.ShapeType.rect, { x: 0.9, y: 1.6, w: 12.0, h: 2.5, fill: { color: 'DBEAFE' }, line: { color: '93C5FD', pt: 1 } });
slide.addText('A 68-year-old man with diabetes, CKD stage 4, and heart failure requires urgent coronary angiography.', { x: 1.2, y: 2.2, w: 11.4, h: 1.0, fontSize: 20, bold: true, color: '1E3A8A' });
slide.addText('Questions:\n• What factors place him at high CA-AKI risk?\n• What prophylaxis would you use?\n• Which contrast strategy would you choose?', { x: 1.0, y: 4.5, w: 12.0, h: 2.0, fontSize: 19, color: colors.textDark });
addFooter(slide);

// Slide 20: Clinical case 2
slide = pptx.addSlide();
addTitleBar(slide, 'Case Discussion 2');
slide.addShape(pptx.ShapeType.rect, { x: 0.9, y: 1.6, w: 12.0, h: 2.5, fill: { color: 'E0F2FE' }, line: { color: '7DD3FC', pt: 1 } });
slide.addText('A 40-year-old woman with suspected multiple sclerosis is scheduled for MRI with gadolinium. eGFR is 22 mL/min/1.73 m².', { x: 1.2, y: 2.1, w: 11.4, h: 1.1, fontSize: 20, bold: true, color: '075985' });
slide.addText('Questions:\n• What specific safety concern is relevant?\n• How should risk-benefit be discussed?\n• What alternatives or precautions can be considered?', { x: 1.0, y: 4.5, w: 12.0, h: 2.0, fontSize: 19, color: colors.textDark });
addFooter(slide);

// Slide 21: Summary
slide = pptx.addSlide();
addTitleBar(slide, 'Key Take-Home Messages');
slide.addText('• Diagnostic agents are central to modern imaging and decision-making.\n• Iodinated contrast is highly useful but requires renal risk assessment.\n• CA-AKI prevention is built on hydration, dose minimization, and careful patient selection.\n• Gadolinium agents are invaluable in MRI but need caution in severe CKD due to NSF risk.\n• Safe prescribing is a team process: radiology, nephrology, and treating clinicians.', {
  x: 0.9, y: 1.8, w: 12, h: 4.5, fontSize: 21, color: colors.textDark
});
addFooter(slide);

// Slide 22: References
slide = pptx.addSlide();
addTitleBar(slide, 'References (Textbook-Based)');
slide.addText('1. National Kidneys Foundation Primer on Kidney Diseases, 8e. Diagnostic Agents / Radiocontrast Agents section (pp. 374–376).\n2. Harrison’s Principles of Internal Medicine, 22E. Nephrotoxin-associated AKI discussion on diagnostic agents.\n3. Comprehensive Clinical Nephrology, 7th Edition. Contrast-enhanced MRI and gadolinium safety considerations.\n4. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. Notes on diagnostic agent handling and transport interactions.', {
  x: 0.9, y: 1.8, w: 12.1, h: 4.4, fontSize: 16, color: colors.textDark
});
slide.addShape(pptx.ShapeType.roundRect, { x: 0.9, y: 6.0, w: 12.0, h: 0.8, fill: { color: 'E2E8F0' }, line: { color: 'CBD5E1', pt: 1 }, radius: 0.07 });
slide.addText('Prepared for undergraduate medical pharmacology teaching', { x: 1.2, y: 6.27, w: 11.4, h: 0.3, fontSize: 13, color: colors.muted, align: 'center' });
addFooter(slide, 'UG Medical Pharmacology | Diagnostic Agents');

pptx.writeFile({ fileName: '/home/daytona/workspace/diagnostic-agents-ppt/Diagnostic_Agents_UG_Medical.pptx' });